Ascendis Pharma A/S (ASND)
| Market Cap | 7.12B |
| Revenue (ttm) | 161.61M |
| Net Income (ttm) | -640.41M |
| Shares Out | 56.54M |
| EPS (ttm) | -11.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 191,968 |
| Open | 127.34 |
| Previous Close | 127.36 |
| Day's Range | 125.76 - 128.00 |
| 52-Week Range | 64.33 - 129.43 |
| Beta | 0.51 |
| Analysts | Buy |
| Price Target | 139.89 (+11.07%) |
| Earnings Date | Feb 15, 2024 |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/" f... [Read more]
Financial Performance
In 2022, ASND's revenue was 51.17 million, an increase of 557.93% compared to the previous year's 7.78 million. Losses were -583.19 million, 52.0% more than in 2021.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $139.89, which is an increase of 11.07% from the latest price.
News
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President...
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/week
COPENHAGEN, Denmark, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new analyses from the blinded and ongoing open-label extension (OLE) portions of ACcomplisH, t...
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency
– On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared t...
FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism
– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted ...
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan
– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan
Ascendis Pharma Reports Third Quarter 2023 Financial Results
COPENHAGEN, Denmark, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2023 and provided business updates...
Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA Resubmission
• Third Quarter financial results and business update conference call to be held on November 7, 2023 • Resubmission of TransCon PTH NDA for adults with hypoparathyroidism expected before mid-November ...
Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023
— Clinical responses with TransCon IL-2 β⁄γ demonstrated as monotherapy or in combination with checkpoint inhibitor, including in two of three small cell lung cancer patients treated with combination...
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer ...
Ascendis Presents TransCon™ PTH Data at the American Thyroid Association Annual Meeting
– At Week 26, 81% of patients in Phase 3 PaTHway Trial with chronic post-surgical hypoparathyroidism, the most common cause of this disease, achieved independence from conventional therapy while maint...
Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency
- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit
Ascendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic Hypoparathyroidism
- Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024
Ascendis Pharma Reports Second Quarter 2023 Financial Results
COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2023 and provided business updates.
New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
- Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m 2 , the threshold for kidney dysfunction, receiving TransCon PTH experienced eGFR improvement to above 60 mL/min/1.73m...
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes
Ascendis Pharma A/S Announces Three Upcoming Investor Presentations
COPENHAGEN, Denmark, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice Presi...
Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders
TSX: ASND www.ascendantresources.com All matters overwhelmingly approved by shareholders TORONTO , Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX: ASND) (OTCQB: ASND) ("Ascendant" or the "...
Ascendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023
COPENHAGEN, Denmark, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2023 financial results and provide a business update on Tuesday,...
One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023
- Oral presentation of results showed sustained improvements through Week 52, as well as safety and tolerability similar to that previously reported for the initial 26-week blinded portion of the Ph...
Ascendis Pharma Showcases Its Latest Endocrinology Programs, Data, and Research at ENDO 2023
- Endocrinology clinical development progress and research i n growth hormone deficiency, hypoparathyroidism, achondroplasia, and Turner Syndrome will be highlighted
Ascendis Pharma to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, and Scott Smith, Executive Vice Presi...
Ascendis Pharma Opens Compassionate Use Program for TransCon™ PTH (palopegteriparatide) in Germany
– Compassionate use enables treating physicians in Germany to request access to investigational TransCon PTH (palopegteriparatide) for eligible adult patients with hypoparathyroidism
Ascendis Pharma Oncology Program Update Highlights Latest Clinical Data for Product Candidates
– TransCon IL-2 β/γ in Phase 1 clinical trial showed monotherapy clinical activity in heavily pre-treated cancer patients with clear dose dependent response on cytotoxic immune cells
Ascendis Pharma to Host Oncology Program Update on May 31
COPENHAGEN, Denmark, May 25, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will host an Oncology program update for the investment community on Wednesday, May...
Ascendis Pharma Showcases Commitment to Rare Endocrine Diseases at the 25th European Congress of Endocrinology 2023
COPENHAGEN, Denmark, May 13, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will present clinical and research outcomes in hypoparathyroidism and growth hormon...